- Home
- PDCC vs RCEL Comparison
PDCC vs RCEL Comparison
Compare PDCC & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDCC
- RCEL
- Stock Information
- Founded
- PDCC N/A
- RCEL N/A
- Country
- PDCC
- RCEL United States
- Employees
- PDCC N/A
- RCEL N/A
- Industry
- PDCC
- RCEL Medical/Dental Instruments
- Sector
- PDCC
- RCEL Health Care
- Exchange
- PDCC NYSE
- RCEL Nasdaq
- Market Cap
- PDCC 123.0M
- RCEL 136.7M
- IPO Year
- PDCC N/A
- RCEL N/A
- Fundamental
- Price
- PDCC $17.85
- RCEL $5.71
- Analyst Decision
- PDCC
- RCEL Strong Buy
- Analyst Count
- PDCC 0
- RCEL 4
- Target Price
- PDCC N/A
- RCEL $16.50
- AVG Volume (30 Days)
- PDCC N/A
- RCEL 314.8K
- Earning Date
- PDCC N/A
- RCEL 08-07-2025
- Dividend Yield
- PDCC N/A
- RCEL N/A
- EPS Growth
- PDCC N/A
- RCEL N/A
- EPS
- PDCC N/A
- RCEL N/A
- Revenue
- PDCC N/A
- RCEL $71,661,000.00
- Revenue This Year
- PDCC N/A
- RCEL $57.16
- Revenue Next Year
- PDCC N/A
- RCEL $36.69
- P/E Ratio
- PDCC N/A
- RCEL N/A
- Revenue Growth
- PDCC N/A
- RCEL 41.35
- 52 Week Low
- PDCC N/A
- RCEL $4.71
- 52 Week High
- PDCC N/A
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- PDCC N/A
- RCEL 49.89
- Support Level
- PDCC N/A
- RCEL $5.13
- Resistance Level
- PDCC N/A
- RCEL $5.87
- Average True Range (ATR)
- PDCC 0.00
- RCEL 0.31
- MACD
- PDCC 0.00
- RCEL 0.14
- Stochastic Oscillator
- PDCC 0.00
- RCEL 83.19
About PDCC PEARL DIVER CREDIT COMPANY INC
PEARL DIVER CREDIT COMPANY INC is an externally managed, non-diversified, closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation by investing predominantly in third-party Collateralized Loan Obligation (CLO) equity and mezzanine tranches of predominately U.S.-dollar-denominated CLOs backed by corporate leveraged loans issued mainly to U.S. obligors.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.